What Researchers Did
Researchers developed a Markov decision analysis model to evaluate the cost-utility of adding hyperbaric oxygen therapy to standard wound care for diabetic foot ulcers in India.
What They Found
Adding hyperbaric oxygen therapy (HBOT) to standard wound care (SWC) reduced minor lower extremity amputations by 6.1% and major amputations by 4.2%. However, the discounted incremental cost-effectiveness ratio was US$2,621 per quality-adjusted-life-year gained, indicating that SWC plus HBOT is not cost-effective in India.
What This Means for Canadian Patients
While hyperbaric oxygen therapy may reduce amputations for diabetic foot ulcers, its cost-effectiveness in the Canadian healthcare system would need separate evaluation. Canadian patients should discuss all treatment options with their healthcare providers, considering both clinical benefits and local economic factors.
Canadian Relevance
This study has no direct Canadian connection as it specifically evaluated cost-utility from a societal perspective in India.
Study Limitations
The study's findings are based on a Markov decision analysis model using existing literature and secondary data, which may not fully capture all real-world complexities or patient experiences.